

# Oxygen-regulated isoforms of cytochrome *c* oxidase have differential effects on its nitric oxide production and on hypoxic signaling

Pablo R. Castello, Dong Kyun Woo, Kerri Ball, Jay Wojcik, Laura Liu, and Robert O. Poyton\*

Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, CO 80309-0347

Edited by Joan Selverstone Valentine, University of California, Los Angeles, CA, and approved February 26, 2008 (received for review October 8, 2007)

Recently, it has been reported that mitochondria possess a novel pathway for nitric oxide (NO) synthesis. This pathway is induced when cells experience hypoxia, is nitrite ( $\text{NO}_2^-$ )-dependent, is independent of NO synthases, and is catalyzed by cytochrome *c* oxidase (Cco). It has been proposed that this mitochondrially produced NO is a component of hypoxic signaling and the induction of nuclear hypoxic genes. In this study, we examine the  $\text{NO}_2^-$ -dependent NO production in yeast engineered to contain alternative isoforms, Va or Vb, of Cco subunit V. Previous studies have shown that these isoforms have differential effects on oxygen reduction by Cco, and that their genes (*COX5a* and *COX5b*, respectively) are inversely regulated by oxygen. Here, we find that the Vb isozyme has a higher turnover rate for NO production than the Va isozyme and that the Vb isozyme produces NO at much higher oxygen concentrations than the Va isozyme. We have also found that the hypoxic genes *CYC7* and *OLE1* are induced to higher levels in a strain carrying the Vb isozyme than in a strain carrying the Va isozyme. Together, these results demonstrate that the subunit V isoforms have differential effects on  $\text{NO}_2^-$ -dependent NO production by Cco and provide further support for a role of Cco in hypoxic signaling. These findings also suggest a positive feedback mechanism in which mitochondrially produced NO induces expression of *COX5b*, whose protein product then functions to enhance the ability of Cco to produce NO in hypoxic/anoxic cells.

hypoxia | mitochondria | reactive oxygen species | nitrite | yeast

It has been known for quite some time that the mitochondrial respiratory chain is capable of generating reactive oxygen species (ROS) that account for much of the oxidative stress experienced by cells (1–3). The levels of these ROS increase when electron flow through the respiratory chain is inhibited by respiratory inhibitors (4–6) or altered by uncoupling electron transport from oxidative phosphorylation (7, 8). Several studies have shown that exposure of cells and tissues to hypoxia increases ROS levels and oxidative stress (9–11). This increase in oxidative stress during exposure to hypoxia depends on a functional mitochondrial respiratory chain (10). It is currently unclear whether this increase is the result of increased generation or decreased destruction of ROS under hypoxic conditions. In yeast cells, the increase in ROS levels and oxidative stress is transient, as determined by shifting cells from normoxia to anoxia (10). During this shift, cells experience a continuum of decreasing oxygen concentrations and a transient increase in the levels of carbonylation of both mitochondrial and cytosolic protein, an increase in 8-OH-dG levels in mtDNA, and an increase in expression of the *SOD1* gene. Many of the proteins that are carbonylated during a shift from normoxia to anoxia are the same proteins that are carbonylated when cells are exposed to menadione, a redox recycling agent that produces elevated intracellular levels of superoxide (12). When considered together, these findings indicate that cellular exposure to hypoxia during a shift from normoxia to anoxia results in increased levels of ROS.

The mitochondrial respiratory chain and cytochrome *c* oxidase (Cco) have been implicated in the induction of some hypoxic nuclear genes (hypoxic signaling) in both yeast and mammalian cells (13–16) exposed to reduced oxygen levels, and it has been proposed that mitochondrially generated ROS are involved (17–20). However, recent studies have revealed that ROS are not sufficient for the induction of hypoxic nuclear genes (R. Dirmeier and R.O.P., unpublished work), suggesting that the respiratory chain has an additional role in hypoxic signaling (21). An important hint concerning an additional role for the mitochondrion in hypoxic signaling comes from the findings that mitochondria from yeast, rat liver, and plants are capable of  $\text{NO}_2^-$ -dependent NO synthesis (21–26). This pathway is induced when cells experience hypoxia, is  $\text{NO}_2^-$ -dependent, is independent of NO synthases, requires the mitochondrial respiratory chain, and in yeast cells is affected by YHb, a flavohemoprotein that functions as a NO oxidoreductase (21). As proposed recently (21) mitochondrially produced NO functions in a signaling pathway to the nucleus by reacting with the superoxide produced by hypoxic mitochondria (10) to form peroxynitrite ( $\text{ONOO}^-$ ), which may directly or indirectly modify specific proteins. These protein modifications may involve tyrosine nitration or the nitrosation of one or more proteins (e.g., HIF-1 $\alpha$ ). Support for the involvement of mitochondrially produced NO in hypoxic signaling in yeast comes from the finding that: (i) an NO donor, 2,2'-(hydroxynitrohydrazono)bisethanimine (DETA-NO), induces the expression of yeast *CYC7*, a hypoxic nuclear gene, in normoxic cells, (ii) *CYC7* is induced earlier and to higher levels in *yhb1*<sup>-</sup> cells than in *YHB1* wild-type cells, (iii) there is an increase in protein-specific tyrosine nitration levels in cells exposed to hypoxia (21), and (iv) neither NO production nor the hypoxic induction of respiration-dependent hypoxic genes occurs in mutants that lack Cco (14, 21). This model also receives support from recent mammalian cells studies that have shown that cytochrome *c*, which is required for mitochondrial  $\text{NO}_2^-$ -dependent NO production, functions to stabilize HIF-1 $\alpha$  in murine cell lines exposed to hypoxia (27).

The  $\text{NO}_2^-$ -dependent mitochondrial NO synthesis in yeast and rat liver mitochondria has been shown to be catalyzed by Cco (21). This activity is observed only at very low oxygen concentrations; which is interesting, because both yeast and mammalian cells respond to hypoxia by producing Cco isozymes with altered activities (28–30). This response is brought about by the differential expression of homologous subunit isoforms whose genes are inversely regulated by  $\text{O}_2$  (30–35). One of these isoforms (either Va or Vb in yeast and IV-1 or IV-2 in mammals) is


Author contributions: P.R.C. and R.O.P. designed research; P.R.C., D.K.W., K.B., J.W., L.L., and R.O.P. performed research; P.R.C. and R.O.P. analyzed data; and P.R.C. and R.O.P. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

\*To whom correspondence should be addressed. E-mail: poyton@spot.colorado.edu.

© 2008 by The National Academy of Sciences of the USA



**Fig. 1.** Phenotypes of strains carrying mutations in *COX5a*, *COX5b*, or *YHB1*. An aliquot (30  $\mu$ g) of mitochondrial protein was subjected to Western immunoblot analysis using polyclonal antibodies made to synthetic peptides corresponding to the carboxyl termini of either subunit V or YHb, as described in *Materials and Methods*.

required for activity of the Cco (33, 36) but is not part of its catalytic center. Under normoxic conditions the aerobic isoform (yeast Va or mammalian IV-1) is expressed, whereas under hypoxic or anoxic conditions the hypoxic isoform (yeast Vb or mammalian IV-2) is expressed (30, 34, 35, 37). Extensive studies with the yeast subunit V isoforms have revealed that the genes (*COX5b* and *COX5a*) for these proteins are switched on or off (respectively) at very low  $O_2$  concentrations (0.5–1  $\mu$ M  $O_2$ ) (31) and that the isoforms affect the catalytic properties of Cco (28, 29). By altering an internal step in electron transfer between heme and the binuclear reaction center the hypoxic isoform, Vb, enhances the turnover number of the enzyme 3- to 4-fold, relative to the aerobic isoform, Va. The inverse regulation of these two isoforms allows cells to assemble different types of Cco isozymes in response to different  $O_2$  concentrations.

Given the recent findings that Cco can produce NO under hypoxic conditions (21) and that the  $O_2$ -regulated subunit isoforms have differential effects on the oxidase activity of Cco, it was of interest to determine whether they affect its NO production as well. It was also of interest to determine whether these isoforms differentially affect the induction of hypoxic genes that require the mitochondrial respiratory chain.

## Results

**Characterization of Strains lacking YHb, Va, and Vb Singly or in Combination.** To ask whether the subunit V isoforms affect the  $NO_2^-$ -dependent NO production by Cco we first examined yeast

cells that express either Va or Vb. We also constructed strains that are deleted for *YHB1* alone or in combination with *COX5a* or *COX5b*. Strains JM43 and DR11 carry functional copies of *COX5a* and *COX5b* but should express mainly *COX5a* when grown under normoxic conditions because *COX5b* expression is repressed by the Rox1p/Reo1p repressor in the presence of air (38–40). DR11 is identical to JM43 except that it carries a *null* mutation in *YHB1* (41). Strain GD5b carries a *null* mutation in *COX5b* (33). Strain DW29 is derived from GD5b and carries a *null* mutation in *YHB1*. Strain CT4F carries a *null* mutation in *COX5a* and the *reo1-4* allele of *REO1/ROX1* (34). This allele allows for the derepression of *COX5b*, but not all hypoxic genes, in normoxic cells (40). DW27 is derived from CT4F and carries a *null* mutation in *YHB1*.

To confirm that these mutant strains contained the desired subunit V isoform, mitochondria from normoxic cells were subjected to Western immunoblot analysis (Fig. 1), using a polyclonal antibody made to a synthetic peptide constructed to correspond to the 20 aa at the carboxyl terminus common to both Va and Vb (29). Because the sequence in this region is identical in both Va and Vb, this antibody should recognize both isoforms equally well after denaturation with SDS. The Va and Vb isoforms are distinguishable on SDS gels by their mobilities: Vb migrates slightly more slowly than Va. As expected, subunit Va is present in the mitochondria of strains JM43, DR11, GD5b, and DW29 and absent in the mitochondria of strains CT4F and DW27 (Fig. 1). In contrast, subunit Vb is present in the mitochondria of strains CT4F and DW27 but absent from the other strains. Strain CT4F and its *yhb1*<sup>-</sup> derivative, DW27, express Vb at a reduced level relative to the level of expression of Va in strain GD5b and its *yhb1*<sup>-</sup> derivative, DW29.

To confirm the presence or absence of YHb in mitochondria from these strains we used a polyclonal antibody (42) made to a 19-aa synthetic peptide whose sequence corresponds to that predicted from the carboxyl terminus of the *YHB1* gene. From Fig. 1 it is clear that YHb can be detected in mitochondria from strains JM43, CT4F, and GD5b but not in the other strains.


**Effect of Subunit V Isoforms and YHb on  $NO_2^-$ -Dependent NO Production in Intact Yeast Cells.** The ability of the strains described above to catalyze  $NO_2^-$ -dependent NO synthesis was assayed under anoxic conditions (Table 1). As expected, little or no NO is produced in the two  $\rho^0$  strains, JM43 $\rho^0$  and DR10, supporting the conclusion made earlier (24) that the  $NO_2^-$ -dependent NO production in intact anoxic yeast cells requires a functional respiratory chain. As observed previously, the presence of YHb

**Table 1.** Effects of subunit V isozymes and YHb on  $NO_2^-$ -dependent NO production in yeast cells

Strain	Subunit V isozyme	YHb	NO production, pmol NO/g wet weight per min*	<i>In vivo</i> turnover rate, pmol NO $\times$ 10 <sup>-1</sup> /min per pmol <i>aa</i> <sub>3</sub> <sup>†</sup>
JM43	Va	+	78 $\pm$ 32	0.07 $\pm$ 0.03
JM43 $\rho^0$	Va	+	00 $\pm$ 20	-
DR11	Va	-	240 $\pm$ 60	0.21 $\pm$ 0.05
DR10	Va	-	20 $\pm$ 10	-
GD5b	Va	+	36 $\pm$ 32	0.04 $\pm$ 0.03
CT4F	Vb	+	114 $\pm$ 32	0.30 $\pm$ 0.08
DW29	Va	-	168 $\pm$ 40	0.18 $\pm$ 0.04
DW27	Vb	-	336 $\pm$ 32	0.89 $\pm$ 0.08

\*Cells (160 mg) were suspended in 2 ml of NO assay buffer and prebubbled for 5 min with  $N_2$  to create anoxic conditions. After 5 min of prebubbling  $NaNO_2$  was added to 1 mM, and NO production was measured with an NO polarographic electrode.


<sup>†</sup>Turnover rate was calculated by normalizing the rate of NO production to the cytochrome *aa*<sub>3</sub> content of each strain, determined as described (31). Intracellular *aa*<sub>3</sub> contents were 5.6  $\mu$ M *aa*<sub>3</sub>/g wet weight for strains JM43 and DR11; 4.6  $\mu$ M *aa*<sub>3</sub>/g wet weight for strains GD5b and DW29, and 1.9  $\mu$ M *aa*<sub>3</sub>/g wet weight for strains CT4F and DW27. Strains JM43  $\rho^0$  and DR10 lack detectable cytochromes *aa*<sub>3</sub>.



**Fig. 2.**  $\text{NO}_2^-$ -dependent NO production by mitochondria from strains DW27, DW29, and JM43 $\rho^0$ . (Left) Isolated mitochondria (400  $\mu\text{g}/\text{ml}$ ) were suspended in NO assay medium, which was prebubbled for 5 min with  $\text{N}_2$  to create anoxic conditions. After 5 min of prebubbling  $\text{NaNO}_2$  was added to 1 mM and NO production was measured with an NO polarographic electrode. (Right) Rates of  $\text{NO}_2^-$ -dependent NO production by mitochondria are normalized to the subunit V content of each strain shown in Left. Mean and standard deviation values are for three independent measurements.

has a profound effect on the rate of whole-cell NO production (21). By comparing the rates of NO production in matched sets of strains [JM43 (*YHB1*)/DR11 (*yhb1*<sup>-</sup>); CT4F (*YHB1*)/DW27 (*yhb1*<sup>-</sup>); and GD5b (*YHB1*)/DW29 (*yhb1*<sup>-</sup>)] it is clear that those strains that lack YHb have rates of NO production that are between 3- and 5-fold higher than those strains that contain YHb (Table 1). It is also clear that those strains (DW27 and CT4F) with the Vb isoform have higher rates of  $\text{NO}_2^-$ -dependent NO production than their counterparts (DW29 and GD5b) with the Va isoform, regardless of whether YHb is present (in strains CF4F and GD5b) or absent (in strains DW27 and DW29). Given that the levels of the Vb isoform in strains CT4F and DW27 are  $\approx 40\%$  of those of the Va isoform in strains GD5b and DW29, the finding that strains CT4F and DW27 have higher rates of NO production than strains GD5b and DW29 is particularly striking. By comparing the rates of NO production in whole cells with their intracellular cytochrome *aa*<sub>3</sub> levels, it is possible to determine the *in vivo* turnover rates for NO production by Cco containing either Va or Vb. These *in vivo* turnover rates for the Vb isozyme are 4.5 to 7 times higher than the turnover rates for the Va isozyme.

**$\text{NO}_2^-$ -Dependent NO Production in Isolated Mitochondria Carrying Va or Vb.** To further analyze the effects of subunit V isoforms we measured  $\text{NO}_2^-$ -dependent NO production in mitochondria isolated from strains JM3 $\rho^0$ , DW27, and DW29. From Fig. 2 Left it is clear that the rate of  $\text{NO}_2^-$ -dependent NO production is higher in mitochondria from a strain (DW27) carrying the Vb isozyme than in mitochondria from a strain (DW29) carrying the Va isozyme. When normalized to the level of subunit V in mitochondria (Fig. 2 Right), the rate of NO production supported by the Vb isozyme is about five times higher than the rate of the Va isozyme, which is similar to the relative rates observed above for whole cells. Mitochondria isolated from JM43 $\rho^0$  lack  $\text{NO}_2^-$ -dependent NO production (Fig. 2 Left). This finding is in agreement with our previous observation (21) that mitochondria from another  $\rho^0$  strain, DR10, also lacks  $\text{NO}_2^-$ -dependent NO production. This finding, together with the observation that the NO production observed with mitochondria from both strains DW27 and DW29 is inhibited by KCN (data not shown), supports our earlier conclusion that a functional mitochondrial respiratory chain is required for  $\text{NO}_2^-$ -dependent NO produc-




**Fig. 3.** Effect of  $\text{NO}_2^-$  concentration on NO production by mitochondria from strains DW27 and DW29. NO production was measured, as described in the legend to Fig. 2, in the presence of different concentrations of added  $\text{NO}_2^-$  (the external concentration). The internal concentration of  $\text{NO}_2^-$  was measured as described in *Materials and Methods*. Mean and standard deviation values are for three independent measurements. The subunit V isozymes present in each mitochondrial preparation are as indicated.

tion in anoxic mitochondria. From Fig. 3 it is clear that increasing  $\text{NO}_2^-$  concentrations support higher rates of NO production by mitochondria from both DW27 and DW29 and that the rates of NO production by mitochondria from DW27, which carries the Vb isozyme, are higher than those in mitochondria from DW29, which carries the Va isozyme, over a wide range of  $\text{NO}_2^-$  concentrations, which fall within the physiological range (21).

**Effects of  $\text{O}_2$  on  $\text{NO}_2^-$ -Dependent NO Production in Mitochondria with Subunit V Isozymes.** To determine whether  $\text{O}_2$  has differential effects on  $\text{NO}_2^-$ -dependent NO production by the Va and Vb isozymes we examined NO production over a range of  $\text{O}_2$  concentrations. These studies were done in a closed chamber in which NO production and dissolved  $\text{O}_2$  concentrations were measured concomitantly. From Fig. 4 Upper it is clear that mitochondria carrying the Vb isozyme are capable of  $\text{NO}_2^-$ -dependent NO production at much higher  $\text{O}_2$  concentrations than mitochondria with the Va isozyme. Indeed, measurable NO production was observed in mitochondria with the Vb isozyme at a dissolved  $\text{O}_2$  concentrations as high as 80% (160  $\mu\text{M}$   $\text{O}_2$  under our assay conditions), whereas NO production in mitochondria carrying the Va isozyme is not observable until the oxygen concentrations drops  $<10\%$  (20  $\mu\text{M}$   $\text{O}_2$  under our assay conditions) (Fig. 4 Lower). These findings indicate that  $\text{O}_2$  is a better inhibitor of  $\text{NO}_2^-$ -dependent NO production by Cco carrying Va than Vb.

**Hypoxic Induction of *CYC7* and *OLE1* Is Altered by Subunit V Isozymes.** Previously, it has been demonstrated that induction of the hypoxic nuclear genes *CYC7* and *OLE1* in yeast cells requires Cco and the respiratory chain (14). It has also been shown that DETA-NO induces the expression of *CYC7* in normoxic cells and that the kinetics of induction of *CYC7* in hypoxic cells is accelerated when *YHB1* is deleted (21). These findings, together with the finding that Cco functions to produce NO under hypoxic and anoxic conditions, suggest that mitochondrially generated NO functions early in a hypoxic signaling pathway that is involved in hypoxic gene induction. To provide more direct support for a link between the NO production by Cco and hypoxic gene induction we asked whether the subunit V isoforms




**Fig. 4.** Effects of oxygen concentration on  $\text{NO}_2^-$ -dependent NO production in mitochondria carrying different subunit V isozymes. Isolated mitochondria from strains DW27 and DW29 were assayed for NO production in assay buffer prebubbled with air in the presence of 1 mM  $\text{NO}_2^-$ . (Upper) NO production was measured with an NO electrode, and dissolved oxygen concentration (DOC) was measured concomitantly with an  $\text{O}_2$  electrode. (Lower) Shown are the rates of NO production as a function of DOC, as determined from the data shown in Upper. The subunit V isozymes present in each mitochondrial preparation are indicated.

affect the induction of hypoxic genes *CYC7* and *OLE1*. If the NO produced by Cco is involved in hypoxic gene induction one would expect that the level of hypoxic gene induction in DW27 and DW29 cells would be different, given that the Vb isozyme has a higher rate of  $\text{NO}_2^-$ -dependent NO production and produces NO at higher concentrations of  $\text{O}_2$  than the Va isozyme. From the data in Fig. 5 it is clear that this is the case. After a shift from normoxia to anoxia strain DW27 supports a much higher level of expression for both *CYC7* and *OLE1* than DW29. This difference lasts for at least 24 h after the shift.

## Discussion

**Cco as a  $\text{NO}_2^-$  Reductase.** The finding that Cco functions to produce  $\text{NO}\cdot$  from  $\text{NO}_2^-$  under hypoxic conditions places it in a group with other hemoproteins that bind  $\text{O}_2$  under normoxic conditions and function in  $\text{NO}_2^-$ -dependent NO production under hypoxic conditions. This group includes hemoglobin and myoglobin (43–47). The rate of NO production by Cco increases with decreasing pH and increasing  $\text{NO}_2^-$  concentration (21), suggesting that Cco functions in a nitrite reductase reaction ( $\text{NO}_2^- + \text{FeII} + \text{H}^+ \rightarrow \text{NO} + \text{FeIII} + \text{OH}^-$ ) similar to that proposed for hemoglobin and myoglobin (48–52). Unlike the Cco oxidase reaction, which requires four electrons, the Cco  $\text{NO}_2^-$  reductase reaction involves a one-electron transfer. Although the precise mechanism of the  $\text{NO}_2^-$  reduction in Cco remains to be determined, it is useful to note that a  $\text{NO}_2^-$ -ferric  $\text{a}_3$  complex has been observed in studies aimed at examining the



**Fig. 5.** Hypoxic induction of *CYC7* and *OLE1* in strains carrying different subunit V isozymes. DW27 and DW29 cells were grown for six generations in midlogarithmic phase to steady state under normoxic conditions in a fermenter. The sparge gas was then changed from air to 97.5%  $\text{N}_2$ , 2.5%  $\text{CO}_2$ . Cells were harvested at the times indicated, their RNA was isolated, and gene expression was analyzed by Q-PCR using primers for *CYC7*, *OLE1*, and *ACT1*. Transcript levels from *CYC7* and *OLE1* were normalized to the transcript from *ACT1*, whose expression is not affected by  $\text{O}_2$ , and are expressed relative to their values at the beginning of the shift from normoxia to anoxia. Mean and standard deviation values are for three independent measurements.

interaction between NO and Cco (53–56). Moreover, it has been reported that a heme–nitrosyl complex is formed at the binuclear reaction center in bovine heart Cco when incubated in the presence of excess  $\text{NO}_2^-$  and reductant (57). These findings suggest that the one-electron reduction of  $\text{NO}_2^-$  to NO occurs at the binuclear reaction center and raise the possibility that under anoxic/hypoxic conditions a step in the catalytic cycle [e.g.,  $\text{NO}\cdot + \text{compound P} (\text{Fe}_{\text{a}_3}^{4+} = \text{O}_2 - \text{Cu}_{\text{B}}^{2+}) \rightarrow \text{Fe}_{\text{a}_3}^{3+} \text{Cu}_{\text{B}} - \text{NO}_2^- \rightarrow \text{NO}_2^-$ ] (58) that is involved in the generation of  $\text{NO}_2^-$  from NO is merely reversed during the reduction of  $\text{NO}_2^-$  to NO, and that the reversal of this reaction is favored at low oxygen levels or the low pHs experienced by anoxic cells (59, 60).

**Differential Effects of Subunit V Isoforms.** The finding here that the Vb isozyme supports a higher level of  $\text{NO}_2^-$ -dependent NO production than the Va isozyme has relevance to the evolution of Cco. Previous studies have concluded that *COX5a* arose from *COX5b* by a gene duplication event that occurred at least 130 million years ago (61). This conclusion makes it likely that oxidase activity of Cco evolved from its  $\text{NO}_2^-$  reductase activity and supports the conclusion that Cco arose, before atmospheric oxygen, from an enzyme whose primary function was in nitrogen metabolism, as suggested by Saraste and coworkers (62, 63). Our finding that  $\text{O}_2$  is a much better inhibitor of the Va isozyme than the Vb isozyme suggests that Va evolved in a way that serves to maximize the ability of Cco to function as an oxidase and conversely, to minimize its ability to produce NO under normoxic conditions.

Previous studies on the differential functions of the Va and Vb isozymes in yeast Cco have revealed that the rate of electron transfer from heme *a* to the binuclear reaction center in the Vb isozyme is 4-fold higher than it is in the Va isozyme but that the activation energies for the two isozymes are the same (28). These findings suggested that the subunit V isoforms alter the protein environment around the binuclear reaction center in such a way as to limit heme Fe<sup>2+</sup>a<sub>3</sub>'s physical accessibility to electrons but without altering the barrier height of the electron transfer reaction. Fourier transform infrared analysis of carbon monoxide liganded to heme Fe<sup>2+</sup>a<sub>3</sub> has been used to further probe the binuclear reaction centers in the subunit V isozymes (29, 64). These studies have revealed a single conformer in the Vb isozyme but two distinct conformers in the Va isozyme, supporting the conclusion that the environment around the binuclear center is different in the Va and Vb isozymes. Modeling studies have suggested that this altered rate occurs via an interaction between transmembrane helix XII of subunit I and the transmembrane helix of subunit V (32). Further insight concerning the effects of the two subunit V isoforms on the binuclear reaction center and the Cco NO<sub>2</sub><sup>-</sup> reductase activity can be gained from analysis of their NO<sub>2</sub><sup>-</sup>-ferric heme a<sub>3</sub> and nitrosyl complexes, as well as the photolability of the heme a<sub>3</sub><sup>2+</sup>-NO complexes of both isozymes to different wavelengths of light (56).

**Subunit V Isozymes and Hypoxic Signaling.** Until recently, the only known function of mitochondrial Cco was in the reduction of dioxygen to water coupled with proton pumping during cellular respiration. Insofar as oxygen is the electron acceptor for this process, it was surprising that gene expression studies with yeast revealed that most COX genes are expressed, albeit at low levels, under anoxic conditions (31, 65). Moreover, the promitochondria from anoxic yeast cells retain significant levels of the polypeptide subunits of Cco (66) and the ability to respire (67). These findings suggested a physiological role for Cco in the absence of O<sub>2</sub>. The recent finding that Cco functions as a NO<sub>2</sub><sup>-</sup> reductase in the presence of reduced oxygen concentrations suggests that this physiological role is to produce NO in hypoxic or anoxic cells. This NO production is likely to be important for physiological adaptation to hypoxia, which requires the induction of several hypoxic nuclear genes (68, 69). In support of NO involvement in hypoxic signaling are the findings that: (i) the respiratory chain and Cco have been implicated in the induction of hypoxic genes in both yeast and mammalian cells (13, 14); (ii) NO production and tyrosine protein nitration increase in hypoxic yeast cells (21) in a respiration-dependent fashion; (iii) NO has a stabilizing effect on HIF-1 $\alpha$  in mammalian cells (70), and (iv) some hypoxic yeast genes in normoxic cells are induced by exogenous NO donors (21). The finding here that the two subunit V isoforms have differential effects on the Cco NO production and on the expression of two different hypoxic genes that have been shown previously to be under the control of the respiratory chain provide further evidence for a link between Cco and hypoxic gene induction.

The expression of *COX5a* and *COX5b* is tightly regulated by oxygen (31). *COX5a* is switched off and *COX5b* is switched on when the O<sub>2</sub> concentration drops below a threshold of 0.5  $\mu$ M O<sub>2</sub>. Insofar as the full induction of *COX5b* under hypoxic conditions depends on a respiratory chain, which contains the Cco Va isozyme (14) when cells are shifted from normoxic to anoxic conditions, it appears that the induction of *COX5b* and expression of its product, Vb, constitutes a positive feedback mechanism in which hypoxia induces the expression of a gene whose product is incorporated into Cco to make it better able to produce NO. It will be interesting to determine whether a similar link can be established for the oxygen-regulated isoforms of mammalian Cco (30) and hypoxic gene induction. Although it is

not yet clear which NO species are involved in hypoxic signaling likely candidates include: peroxyxynitrite, S-nitrosothiols, and NO (71–73). These NO species can function in protein nitration and protein nitrosation.

## Conclusions

The studies described here represent a step toward addressing the mechanism underlying NO production by mitochondrial Cco and the function of the oxygen-regulated subunit V isoforms in this reaction. An in-depth understanding of both mechanisms is crucial to our understanding of hypoxic signaling and the role of NO in the regulation of respiration.

## Materials and Methods

**Strains, Media, and Growth Conditions.** The *Saccharomyces cerevisiae* strains used for this study were: JM43 (*MAT $\alpha$  his4–580 trp1–289 leu2–3, 112 ura3–52 [ $\rho^+$ ]*) (36); JM43 $\rho^0$  (*MAT $\alpha$  his4–580 trp1–289 leu2–3, 112 ura3–52 [ $\rho^0$ ]*) (28); DR11 (*MAT $\alpha$  his4–580 trp1–289 leu2–3, 112 ura3–52, yhb1::URA3 [ $\rho^+$ ]*) (41); DR10 (*MAT $\alpha$  his4–580 trp1–289 leu2–3, 112 ura3–52, yhb1::URA3 [ $\rho^0$ ]*) (41); CT4F (*MAT $\alpha$  his4–580 trp1–289 leu2–3, 112 ura3–52, cox5a $\Delta$ ::URA3, COX5b, reo1–4, [ $\rho^+$ ]*) (34); GD5b (*MAT $\alpha$  his4–580 trp1–289 leu2–3, 112 ura3–52 cox5b::LEU2 [ $\rho^+$ ]*) (34); YDW27 (*MAT $\alpha$  his4–580 trp1–289 leu2–3, 112 ura3–52, cox5a $\Delta$ ::URA3, COX5b, reo1–4, yhb1::Kan<sup>r</sup>, [ $\rho^+$ ]*); and YDW29 (*MAT $\alpha$  his4–580 trp1–289 leu2–3, 112 ura3–52 cox5b::LEU2, yhb1::Kan<sup>r</sup> [ $\rho^+$ ]*). All strains were derived from and are isochromosomal with JM43. Strains YDW27 and YDW29 were constructed for this study by selective deletion of the *YHB1* genes in strains CT4F and GD5b, respectively, using homologous recombination of site-specific cassettes amplified by PCR (74). Deletion cassettes containing the *Escherichia coli kan<sup>r</sup>* gene, which confers resistance to G418/geneticin (75, 76), were used to transform CT4F and GD5b by the lithium acetate procedure (77).

Yeast cells were grown in SSG-TEA, a semisynthetic medium (66), supplemented with Tween 80, ergosterol, silicon antifoam, and amino acids and uracil, as needed (14). Aerobic cultures and precultures were grown in a controlled environment incubator shaker (New Brunswick Scientific) at 200 rpm and 28°C and harvested in midlogarithmic growth phase. Shift experiments between normoxia and anoxia were performed in a New Brunswick BIOFLO 3000 fermentor, as described (78).

**Preparation of Mitochondria.** Mitochondria were prepared from aerobic cultures as described (79). After cell breakage and centrifugation at 2,000  $\times$  g for 3 min, an aliquot of the supernatant was saved as "whole-cell lysate." The rest of the supernatant was decanted and centrifuged for 10 min at 12,000  $\times$  g to pellet the mitochondrial fraction, saving the supernatant as the cytosolic fraction. Oxygen uptake was measured at 30°C with a Strathkelvin oxygen electrode system, as described (78), but with the following modifications: the assay solution consisted of 2 ml of buffer containing 0.65 M Mannitol, 0.01M K<sub>2</sub>HPO<sub>4</sub> (pH 6.5), 0.1 mM EDTA, 0.01 M KCl, 5 mM  $\alpha$ -ketoglutarate, and 0.7 mg of mitochondrial protein. The P:O and respiratory control ratios of mitochondria were determined (49) by measuring oxygen consumption in the presence or absence of ADP and only coupled mitochondria (P:O  $\approx$  2) were used.

**SDS/PAGE and Immunoblot Analysis.** SDS/PAGE was performed on 16% SDS polyacrylamide gels containing 10% glycerol and 3.6 M urea (29). After electrophoresis, proteins were electroblotted to Polyscreen PVDF transfer membrane (PerkinElmer), immunoblotted with a polyclonal antibody to either Yhb (42) or a polyclonal antibody to the carboxyl terminal of subunit V (29), and detected with peroxidase-linked antibodies and a Western Lightning chemiluminescence detection kit (PerkinElmer). The levels of Va and Vb on immunoblots were quantitated by using ImageQuant TL software (GE Healthcare Biosciences).

**Measurement of NO Production.** NO production was measured with a 2-mm Clark-type NO electrode and an APOLLO 4000 NO-meter (WP1) (21). Except where noted, all solutions were NO<sub>2</sub><sup>-</sup> free. Measurements were performed at 28°C with a final reaction volume of 2 ml in a thermostated chamber with a close-fitting lid and fine holes for the electrode and a Hamilton syringe. Assays for NO production by the mitochondrial respiratory chain were performed in NO assay medium [6 mM succinate, 650 mM Mannitol, 10 mM K<sub>2</sub>HPO<sub>4</sub> (pH 6.5), 0.1 mM EDTA, and 10 mM KCl]. Except where noted, the NO assay buffer was prebubbled with N<sub>2</sub> to achieve anoxic conditions before addition of NaNO<sub>2</sub> to a final concentration of 1 mM and the measurement of NO production.

**Measurement of Mitochondrial Internal NO<sub>2</sub><sup>-</sup> Concentration.** Evaluation of NO<sub>2</sub><sup>-</sup> uptake by mitochondria obtained from yeast strains DW27 and DW29 was performed as described (21).

**Quantitative-PCR (Q-PCR).** Total RNA was isolated from yeast cells as described (80). Q-PCR amplification reactions were performed with an iScript cDNA Synthesis Kit (BioRad) following the manufacturer's instructions. Primers were designed against sequences of the indicated mRNAs by using Primer Express 2.0 (Applied Biosystems). An aliquot of 25- $\mu$ l PCRs containing 1 $\times$  SYBR Green Mix (Applied Biosystems), 1 ng of cDNA, and 500 nM primers were set up in 96-well plates. Standard curves from 1–10 ng of cDNA were run alongside

samples for each individual primer, and plates were read in an Applied Biosystems 7900HT Q-PCR instrument (absolute quantification method). Expression quantities were normalized to the *ACT1* transcript.

**Miscellaneous Methods.** Protein concentration was determined by either the Lowry assay (80) or the BCA assay (Pierce Biotechnology) with BSA as a standard.

**ACKNOWLEDGMENTS.** We thank Joaquin M. Espinosa for assistance in the quantitation of genes. This work was supported by National Institutes of Health Grant GM 30228 (to R.O.P.).

1. Boveris A, Chance B (1973) *Biochem J* 134:707–716.
2. Cadenas E (1989) *Annu Rev Biochem* 58:79–110.
3. Turrens JF (2003) *J Physiol (London)* 552:335–344.
4. Bandy B, Davison AJ (1990) *Free Radical Biol Med* 8:523–539.
5. St-Pierre J, Buckingham JA, Roebuck SJ, Brand MD (2002) *J Biol Chem* 277:44784–44790.
6. Turrens JF, Alexandre A, Lehninger AL (1985) *Arch Biochem Biophys* 237:408–414.
7. Brand MD, Esteves TC (2005) *Cell Metab* 2:85–93.
8. Starkov AA (2006) *Chem Biol Interact* 161:57–68.
9. Chandel NS, Budinger GR (2007) *Free Radical Biol Med* 42:165–174.
10. Dirmeier R, O'Brien KM, Engle M, Dodd A, Spears E, Poyton RO (2002) *J Biol Chem* 277:34773–34784.
11. Grishko V, Solomon M, Breit JF, Killilea DW, LeDoux SP, Wilson GL, Gillespie MN (2001) *FASEB J* 15:1267–1269.
12. Cabiscol E, Piulats E, Echave P, Herrero E, Ros J (2000) *J Biol Chem* 275:27393–27398.
13. Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, Schumacker PT (1998) *Proc Natl Acad Sci USA* 95:11715–11720.
14. Kwast KE, Burke PV, Staahl BT, Poyton RO (1999) *Proc Natl Acad Sci USA* 96:5446–5451.
15. Poyton RO (1999) *Respir Physiol* 115:119–133.
16. Poyton RO, Dirmeier R, O'Brien K, Spears E (2003) in *Oxygen Sensing: Responses and Adaptation to Hypoxia*, eds Lahiri S, Semenza GL, Prabhakar NR (Dekker, New York), pp 23–45.
17. Chandel NS, McClintock DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, Schumacker PT (2000) *J Biol Chem* 275:25130–25138.
18. Brunelle JK, Bell EL, Quesada NM, Vercauteren K, Tiranti V, Zeviani M, Scarpulla RC, Chandel NS (2005) *Cell Metab* 1:409–414.
19. Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, Simon MC, Hammerling U, Schumacker PT (2005) *Cell Metab* 1:401–408.
20. Kaelin WG, Jr (2005) *Cell Metab* 1:357–358.
21. Castello PR, David PS, McClure T, Crook Z, Poyton RO (2006) *Cell Metab* 3:277–287.
22. Gupta KJ, Stoimenova M, Kaiser WM (2005) *J Exp Bot* 56:2601–2609.
23. Nohl H, Staniek K, Sobhian B, Bahrami S, Redl H, Kozlov AV (2000) *Acta Biochim Pol* 47:913–921.
24. Nohl H, Staniek K, Kozlov AV (2005) *Redox Rep* 10:281–286.
25. Planchet E, Jagadis GK, Sonoda M, Kaiser WM (2005) *Plant J* 41:732–743.
26. Tischner R, Planchet E, Kaiser WM (2004) *FEBS Lett* 576:151–155.
27. Mansfield KD, Guzy RD, Pan Y, Young RM, Cash TP, Schumacker PT, Simon MC (2005) *Cell Metab* 1:393–399.
28. Waterland RA, Basu A, Chance B, Poyton RO (1991) *J Biol Chem* 266:4180–4186.
29. Allen LA, Zhao XJ, Caughey W, Poyton RO (1995) *J Biol Chem* 270:110–118.
30. Fukuda R, Zhang H, Kim JW, Shimoda L, Dang CV, Semenza GL (2007) *Cell* 129:111–122.
31. Burke PV, Raitt DC, Allen LA, Kellogg EA, Poyton RO (1997) *J Biol Chem* 272:14705–14712.
32. Burke PV, Poyton RO (1998) *J Exp Biol* 201:1163–1175.
33. Trueblood CE, Poyton RO (1987) *Mol Cell Biol* 7:3520–3526.
34. Trueblood CE, Poyton RO (1988) *Genetics* 120:671–680.
35. Trueblood CE, Wright RM, Poyton RO (1988) *Mol Cell Biol* 8:4537–4540.
36. Cumsky MG, Ko C, Trueblood CE, Poyton RO (1985) *Proc Natl Acad Sci USA* 82:2235–2239.
37. Poyton RO, Burke PV (1992) *Biochim Biophys Acta* 1101:252–256.
38. Zitomer RS, Limbach MP, Rodriguez-Torres AM, Balasubramanian B, Deckert J, Snow PM (1997) *Methods* 11:279–288.
39. Zitomer RS, Carrico P, Deckert J (1997) *Kidney Int* 51:507–513.
40. Kwast KE, Burke PV, Brown K, Poyton RO (1997) *Curr Genet* 32:377–383.
41. Zhao XJ, Raitt D, Burke V, Clewell AS, Kwast KE, Poyton RO (1996) *J Biol Chem* 271:25131–25138.
42. Cassanova N, O'Brien KM, Stahl BT, McClure T, Poyton RO (2005) *J Biol Chem* 280:7645–7653.
43. Copeland DM, Soares AS, West AH, Richter-Addo GB (2006) *J Inorg Biochem* 100:1413–1425.
44. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, Waclawiw MA, Zalos G, Xu X, et al. (2003) *Nat Med* 9:1498–1505.
45. Nagababu E, Ramasamy S, Abernethy DR, Rifkind JM (2003) *J Biol Chem* 278:46349–46356.
46. Reutov VP, Sorokina EG (1998) *Biochemistry (Mosc)* 63:874–884.
47. Shiva S, Huang Z, Grubina R, Sun J, Ringwood LA, MacArthur PH, Xu X, Murphy E, Darley-Usmar VM, Gladwin MT (2007) *Circ Res* 100:654–661.
48. Sulc F, Immoos CE, Pervitsky D, Farmer PJ (2004) *J Am Chem Soc* 126:1096–1101.
49. Doyle MP, Pickering RA, DeWeert TM, Hoekstra JW, Pater D (1981) *J Biol Chem* 256:12393–12398.
50. Bryan NS (2006) *Free Radical Biol Med* 41:691–701.
51. Grubina R, Huang Z, Shiva S, Joshi MS, Azarov I, Basu S, Ringwood LA, Jiang A, Hogg N, Kim-Shapiro DB, et al. (2007) *J Biol Chem* 282:12916–12927.
52. Grubina R, Basu S, Tiso M, Kim-Shapiro DB, Gladwin MT (2008) *J Biol Chem* 283:3628–3638.
53. Cooper CE, Torres J, Sharpe MA, Wilson MT (1997) *FEBS Lett* 414:281–284.
54. Torres J, Sharpe MA, Rosquist A, Cooper CE, Wilson MT (2000) *FEBS Lett* 475:263–266.
55. Giuffrè A, Barone MC, Mastronicola D, D'Itri E, Sarti P, Brunori M (2000) *Biochemistry* 39:15446–15453.
56. Sarti P, Giuffrè A, Forte E, Mastronicola D, Barone MC, Brunori M (2000) *Biochem Biophys Res Commun* 274:183–187.
57. Brudvig GW, Stevens TH, Chan SI (1980) *Biochemistry* 19:5275–5285.
58. Brunori M, Forte E, Arese M, Mastronicola D, Giuffrè A, Sarti P (2006) *Biochim Biophys Acta* 1757:1144–1154.
59. Campbellburk SL, Denhollander JA, Alger JR, Shulman RG (1987) *Biochemistry* 26:7493–7500.
60. Gonzalez B, de Graaf A, Renaud M, Sahn H (2000) *Yeast* 16:483–497.
61. Cumsky MG, Trueblood CE, Ko C, Poyton RO (1987) *Mol Cell Biol* 7:3511–3519.
62. Castresana J, Lubben M, Saraste M, Higgins DG (1994) *EMBO J* 13:2516–2525.
63. Saraste M, Castresana J (1994) *FEBS Lett* 341:1–4.
64. Zhao XJ, Caughey WS, Poyton RO (1995) *Methods Enzymol* 260:399–406.
65. Kwast KE, Burke PV, Poyton RO (1998) *J Exp Biol* 201:1177–1195.
66. Dagsgaard C, Taylor LE, O'Brien KM, Poyton RO (2001) *J Biol Chem* 276:7593–7601.
67. David PS, Poyton RO (2005) *Biochim Biophys Acta* 1709:169–180.
68. Bunn HF, Poyton RO (1996) *Physiol Rev* 76:839–885.
69. Wenger RH (2000) *J Exp Biol* 203:1253–1263.
70. Li F, Sonveaux P, Rabbani ZN, Liu S, Yan B, Huang Q, Vujaskovic Z, Dewhirst MW, Li CY (2007) *Mol Cell* 26:63–74.
71. El-Remessy AB, Al-Shabraway M, Platt DH, Bartoli M, Behzadian MA, Ghaly N, Tsai N, Motamed K, Caldwell RB (2007) *FASEB J* 21:2528–2539.
72. Gaston B, Singel D, Doctor A, Stamler JS (2006) *Am J Respir Crit Care Med* 173:1186–1193.
73. Palmer LA, Doctor A, Chhabra P, Sheram ML, Laubach VE, Karlinsey MZ, Forbes MS, Macdonald T, Gaston B (2007) *J Clin Invest* 117:2592–2601.
74. Longtine MS, McKenzie A, III, Demarini DJ, Shah NG, Wach A, Brachat A, Philippsen P, Pringle JR (1998) *Yeast* 14:953–961.
75. Jimenez A, Davies J (1980) *Nature* 287:869–871.
76. Hadfield C, Jordan BE, Mount RC, Pretorius GH, Burak E (1990) *Curr Genet* 18:303–313.
77. Ito H, Fukuda Y, Murata K, Kimura A (1983) *J Bacteriol* 153:163–168.
78. Poyton RO, Dirmeier R, O'Brien K, David P, Dodd A (2004) *Methods Enzymol* 381:644–662.
79. McKey EE, Poyton RO (1984) *J Biol Chem* 259:9320–9331.
80. Lowry OH, Rosebrough NJ, Farral AL, Randall RJ (1951) *J Biol Chem* 193:265–275.